Literature DB >> 12727844

Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.

Nancy J Nesslinger1, Xu-Bao Shi, Ralph W deVere White.   

Abstract

Mutations of p53 are common in hormone-refractory prostate cancer (CaP), suggesting the possibility that these mutations may be involved in the progression of CaP to androgen-independent (AI) growth. However, at present no direct evidence has been presented linking p53 mutations with AI growth of CaP. We established five stably transfected LNCaP cell lines: four containing gain-of-function (GOF) mutant p53 alleles (G245S, R248W, R273H, and R273C) and one containing a non-GOF p53 mutant allele (P151S). The four GOF p53 sublines were able to grow under androgen-depleted conditions, whereas the LNCaP parental line, vector-only line, and the non-GOF line were unable to grow. To investigate the mechanism of the AI growth displayed by the GOF p53 mutants, Western blotting or ELISA were used to examine the expression of the androgen receptor (AR), the AR-regulated prostate-specific antigen (PSA), as well as Akt and Bcl-2 under androgen-depleted conditions. On androgen ablation, the levels of AR decreased in the four GOF p53 sublines compared with the control lines. This decreased AR expression was accompanied by attenuated receptor activity, because a decrease in prostate-specific antigen levels compared with parental LNCaP cells was also observed. Levels of phosphorylated Akt increased in both the GOF p53 sublines and the control lines. Bcl-2 remains unchanged or showed reduced expression in all of the cell lines in the absence of androgen compared to the presence of androgen. These observations suggest that GOF p53 mutants mediate the AI growth of LNCaP cells in an AR-independent fashion, and that both Akt and Bcl-2 are not involved in this process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727844

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.

Authors:  Byron Hann; Allan Balmain
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.

Authors:  Yuexing Zhang; Xin-Wei Wang; Danijela Jelovac; Takeo Nakanishi; Myoung-Hee Yu; Damilola Akinmade; Olga Goloubeva; Douglas D Ross; Angela Brodie; Anne W Hamburger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-30       Impact factor: 11.205

3.  Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching.

Authors:  Yirong Li; David Y Zhang; Qinghu Ren; Fei Ye; Xin Zhao; Garrett Daniels; Xinyu Wu; Brian Dynlacht; Peng Lee
Journal:  Mol Cell Biol       Date:  2012-04-16       Impact factor: 4.272

4.  Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.

Authors:  Tong-Xin Xie; Ge Zhou; Mei Zhao; Daisuke Sano; Samar A Jasser; Richard G Brennan; Jeffrey N Myers
Journal:  Laryngoscope       Date:  2013-04-26       Impact factor: 3.325

5.  miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.

Authors:  Xu-Bao Shi; Lingru Xue; Ai-Hong Ma; Clifford G Tepper; Hsing-Jien Kung; Ralph W deVere White
Journal:  Prostate       Date:  2010-09-30       Impact factor: 4.104

Review 6.  Molecular staging of prostate cancer in the year 2007.

Authors:  Thorsten Schlomm; Andreas Erbersdobler; Martina Mirlacher; Guido Sauter
Journal:  World J Urol       Date:  2007-03-02       Impact factor: 4.226

7.  Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.

Authors:  Thirupandiyur S Udayakumar; Paul Hachem; Mansoor M Ahmed; Sudhir Agrawal; Alan Pollack
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

8.  Expression of androgen receptor is negatively regulated by p53.

Authors:  Fatouma Alimirah; Ravichandran Panchanathan; Jianming Chen; Xiang Zhang; Shuk-Mei Ho; Divaker Choubey
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

9.  MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.

Authors:  Christian Tovar; Brian Higgins; Kenneth Kolinsky; Mingxuan Xia; Kathryn Packman; David C Heimbrook; Lyubomir T Vassilev
Journal:  Mol Cancer       Date:  2011-05-03       Impact factor: 27.401

10.  Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.

Authors:  Ruth L Vinall; Jane Q Chen; Neil E Hubbard; Shola S Sulaimon; Michael M Shen; Ralph W Devere White; Alexander D Borowsky
Journal:  Dis Model Mech       Date:  2012-04-12       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.